Objec9ves. Drug Classes with Indications to Treat AR. Allergic Rhinitis. Allergic Rhinitis. Action Statements
|
|
- Buddy Adams
- 5 years ago
- Views:
Transcription
1 Sneezes, Wheezes, and espiratory Diseases: An update on Asthma, Allergic hini5s, and COPD Amelie Hollier, DNP, FNP-BC, FAANP Advanced Practice Education Associates Objec9ves Evalua9on of the latest allergic rhini9s guidelines and medica9ons (10 mins) Evalua9on of the medica9ons used to treat asthma and COPD (25 mins) Develop strategies for management of pa9ents who have combina9ons of these diseases (25 mins) Allergic hinitis 5 th most common chronic disease in US Affects 1 in 6 people Treatment costs: $2-5 Billion annually Allergic hinitis an inflammatory response of the nasal mucous membranes after inhaling an allergen, such as grass pollen, dust mites, pet dander,. Symptoms include runny nose, congestion, sneezing, itching Otolaryngol Head Neck Surg Feb;152(1 Suppl):S1-43. Otolaryngol Head Neck Surg Feb;152(1 Suppl):S1-43. Action Statements Strong ecommendation: Intranasal steroids first line Second generation oral antihistamines for sneezing and itching Drug Classes with Indications to Treat A Intranasal glucocorticoids (INGCs) Oral antihistamines Antihistamine sprays Mast cell stabilizers Leukotriene modifiers Otolaryngol Head Neck Surg Feb;152(1 Suppl):S
2 Intranasal Glucocorticoids INGCs THE single most effective therapy for nasal symptoms Downregulate the inflammatory response Fewest side effects Best use in nasal congestion Superior efficacy compared to antihistamines Why do they work? Inhibit allergic inflammation in nose Downregulate inflammatory responses by binding to the glucocorticoid receptors in the cytoplasm of the inflammatory cells Intranasal Glucocorticoids Divided into Generations 1st Generations INGCs First Generation (unknown bioavailability): Beclomethasone (Beconase) Equal efficacy as other INGCs Higher risk of systemic effects because of greater bioavailability 2nd Generations INGCs 2nd Generation (10-34% bioavailability): Budesonide Equal efficacy as other INGCs Potentially fewer systemic effects compared to 1 st generation 3rd Generations INGCs 3rd Generation INGCs: Fluticasone proprionate (<2% bioavailability) Mometasone (undetectable) Fluticasone furoate (<1%) Ciclesonide (minimal) No or limited effect of HPA axis and growth in children 2
3 NAME Generic? Brand Name Fluticasone proprionate Yes Flonase Mometasone Yes Nasonex Budesonide Yes hinocort AQ Beclomethasone No Qnasl Triamcinolone Yes Nasacort AQ Beclomethasone No Beconase AQ Fluticasone furoate No Veramyst Ciclesonide AQ No Omnaris Ciclesonide (dry spray) No Zetonna Comparisons between INGCs Comparative studies between INGCs have not demonstrated significant differences in efficacy Berger, Kaiser, Gawchik, Tillinghast, Woodworth, Dupclay, Georges. Otolaryngol Head Neck Surg. 2003; 129(1):16. Prescribers Letter, March 2015; Vol:31. Allergic hinitis. Determination of Efficacy First pass metabolism: decreases drug bioavailability Fluticasone furoate (Veramyst) June, 2007 Me too drugs Contains fluticasone furoate instead of fluticasone propionate No evidence that furoate is more efficacious than propionate Lipophilicity: ability of GC to penetrate the cell Fluticasone furoate Fluticasone furoate is unscented, no bad taste or smell Improves nasal symptoms, improves eye symptoms $ (27.5 mcg/spray) Ciclesonide Nasal (Omnaris) New steroid Hypotonic solution Hypothesized to increase retention and local absorption at the nasal mucosa $94.49 June,
4 Beclomethasone Nasal (Qnasal) Uses HFA propellant like asthma inhalers Non-aqueous Less PND than with aq sprays 44% systemic absorption Once daily $130/month May, 2012 Get the Drug Where it Needs to Work! Drug must remain in the nose (not down the back of the throat) If nose is crusted or contains mucus, get it out!!! Use saline PN Look at your Toes and Spray your Nose! Best way to instill Direct away from the nasal septum Sniff to pull into upper parts of nose If it drains down the throat, sniff was too hard! eassurance for Long Term Use No increased rate of fractures, glaucoma, or cataracts No detrimental effects on bone density or intraocular pressure Ann Allergy, Asthma, Immunol 2006; 96:1. Quiz When to Use INGCs? When is the best time of day (or night) to use a nasal INGC? Evening/PM Nasal inflammation is greater at night than during the day Ann Allergy, Asthma, Immunol 2006; 96:1. 4
5 OTC Meds for Allergic hini9s FDAs non- x Drugs Advisory CommiPee Triamcinolone acetonide (Nasacort Allergy 24H) for OTC status: (available Spring 2014) Flu9casone propionate (Flonase Allergy elief): available early 2015 Allergic hini9s Hhhhmmmm.Insurance issues with x topical nasal steroids? $ $27.99 OTC Generic cost to you? Action Statements Strong ecommendation: Intranasal steroids first line Second generation oral antihistamines for sneezing and itching Anti-histamines (AH) Why Not First Genera9on An9- histamines? Otolaryngol Head Neck Surg Feb;152(1 Suppl):S st Generation AH Diphenhydramine Chlorpheniramine Hydroxyzine Brompheniramine Cyproheptadine Others 1st Generation AH Cause significant sedation They are lipophilic and cross the blood brain barrier 5
6 1st Generation AH Intellectual and motor function impairment are present even when there is no subjective awareness of sedation 1st Generation AH Prohibited by the FAA for working pilots Prohibited in many states for any person who works in public transportation Older patients more susceptible to anticholinergic effects (dry eyes and mouth, urinary hesitancy, and confusion) 2nd Generation AH Oral Agents Loratadine, desloratadine, cetirizine, levocetirizine, fexofenadine (orals) Mostly non-sedating Lipophobic (so don t cross BB barrier as the 1st gens do) Less impact on nasal congestion 2nd Generation AH Fexofenadine (metabolite of terfenadine) Desloratadine (loratadine) Levocetirizine (purified isomer of cetirizine) Adverse Effects: Sedation Cetirizine, levocetirizine and azelastine are sedating for many patients Loratadine mostly non-sedating Adverse Effects Fexofenadine is non-sedating even at higher than recommended doses 6
7 2 nd Generations Less effective than topical nasal steroids for allergic rhinitis All oral 2nd generation agents have similar efficacies Options Clinicians may offer: Intranasal antihistamines seasonal, perennial, or episodic allergic rhinitis Otolaryngol Head Neck Surg Feb;152(1 Suppl):S nd Generation AH Sprays Azelastine (generic) (Astelin), olopatadine (Patanase) Can be sedating apid onset of action (< 15 minutes) Some anti inflammatory effects Improve nasal congestion PN use Bitter taste Watch out for Medication Errors with Olopatadine! Patanase 0.6%: Nasal spray Patanol 0.1% and Pataday 0.2%: Ophthalmic drops Can be sedating if swallowed Azelastine/ fluticasone(dymista) Jan, 2012 Combines 2 generic meds Steroid plus antihistamine 1 spray each nostril BID Action Statements ecommendation: Clinicians should offer, or refer to a clinician who can offer, immunotherapy (sublingual or subcutaneous) for patients with A who have inadequate response to symptoms with pharm therapy. Otolaryngol Head Neck Surg Feb;152(1 Suppl):S
8 Grass Pollen Extracts Grastek: grass pollen allergen extract Oralair: grass pollen allergen extract Sublingual immunotherapy for allergic rhini9s > $200/month Allergic hini9s agwitek: ragweed pollen allergen extract Sublingual immunotherapy for rhini9s Must have documented allergies before prescribing (Companies that will do this for primary care) Action Statements ecommended Against: Oral leukotriene receptor antagonists as primary therapy for patients with allergic rhinitis. Chronic Obstructive Pulmonary 2014 Global Ini9a9ve for Chronic Obstruc9ve Lung Disease (GOLD) A report by NHLBI and WHO to define, diagnose, treat COPD Otolaryngol Head Neck Surg Feb;152(1 Suppl):S GOLD Staging System The Global Initiative for COPD COPD Medications Most Commonly Used: Inhaled Beta 2 -agonists: short and long Inhaled Anticholinergics (AC): short and long Combo: short Beta 2 and short AC Combo: long Beta 2 and long AC 8
9 Quiz Which long-acting medication class is preferred first line for a patient with COPD who complains of frequent SOB: Beta agonists or Anticholinergics? COPD Medications Others Methylxanthines Inhaled corticosteroids: solo and combo with Beta 2 Systemic steroids Phosphodiesterase-4 Inhibitors Bronchodilators 1. Beta agonists (cause bronchodilation): Short acting beta agonists (SABAs) Example: albuterol Suffix is terol escue med (works immediately and effects last for about 4 hours) Bronchodilators SABAs Albuterol ProAir HFA, Proventil HFA, Ventolin HFA, Levalabuterol (Xopenex), ProAir espiclick (inhalation powder) $42 - $56 per inhaler True or False Levalbuterol is more effective than albuterol. What s the difference between the ß-2s? Drug ß-2 potency Onset in minutes Duration in hrs Albuterol 2 Within Pirbuterol (MaxAir Autohaler) 5 Within 5 5 Levalbuterol??? Within 5 8 9
10 What s the relationship between levalbuterol (Xopenex ) and albuterol? isomer ===> bronchodilation S isomer ===> tachycardia,etc. Albuterol is a mixture of and S isomers Levalbuterol is -isomer of albuterol Albuterol is a mixture of and S isomers S S S S S S Albuterol Xopenex Levalbuterol (Xopenex ) -isomer of albuterol Albuterol is a mixture of and S isomers Levalbuterol (Xopenex ) Inconclusive whether there are fewer side effects for the degree of bronchodilation Older adults: inconclusive More expensive than albuterol Levalbuterol (Xopenex ) Studies of children who use levalbuterol have failed to demonstrate an advantage with levalbuterol More expensive than albuterol Long acting beta agonists (LABAs) Salmeterol (Serevent ), formoterol (Foradil ): Twice Daily Indacaterol (Arcapta Neohaler), Olodaterol (Striverdi espimat): Once Daily Suffix is terol Not a rescue med (takes mins to work) but works for hours 10
11 LABA Dosing Frequency Cost Formoterol (Foradil) Salmeterol (Serevent) Indacaterol (Arcapta Neohaler) Olodaterol (Striverdi espimat) BID $ BID $ Daily $ Daily $ LABAs More convenient and more effec9ve for symptom relief educe exacerba9ons and hospitaliza9ons Improve symptoms Improve health status Bronchodilators 2. Inhaled Anticholinergic Works by preventing bronchoconstriction (yeah, ok it bronchodilates a little) Examples: Ipratropium (Atrovent), tiotropium (Spiriva), aclidinium (Tudorza Pressair), Umeclidinium (Incruse Ellipta) Suffix is tropium Combos: with SABA, LABA, May cause constipation, increased IOP Long Ac9ng An9cholinergic (LAAC) Aclidinium (Turdoza Pressair) Tiotropium Spiriva Handihaler Spiriva espimat Umeclidinium (Incruse Ellipta) Dosing Frequency Cost BID $ Daily $ Daily $ An9cholinergic Medica9ons An5- cholinergic Side Effects Memory impairment, confusion, hallucina9ons, dry mouth, blurred vision, urinary reten9on, cons9pa9on, tachycardia, acute angle glaucoma An Ode to an An9cholinergic Med Oh this drug, it makes me pink, Some9mes, I can t think or even blink. I can t see, I can t pee, I can t spit, I can t (**it) ( defecate ). 11
12 Combo LABA and LAAC Combo Dosing Frequency Cost Olodaterol/ Tiotroprium (S9olto espimat) Vilanterol/ Umeclidinium (Anoro Ellipta) Daily $ Daily $ : 3. Inhaled Pharmacologic Steroids Management Best in COPDers with FEV1 <60% predicted Increases risk of pneumonia Withdrawal may lead to exacerbations Examples: fluticasone, mometasone, budesonide, others Suffix is one or ide Best in combo with bronchodilators Steroid Pharmacologic Combos Management 4. Steroid plus bronchodilators Combined mechanism as for steroid and bronchodilators Examples: fluticasone plus salmeterol (Advair), budesonide plus formoterol (Symbicort), mometasone plus salmeterol (Dulera) No generics, very expensive!!! Oral Steroids CHONIC use should be avoided!!! Unfavorable risk to benefit ratio Oral Steroids for Exacerbations Shorten recovery 9me Improve lung func9on (FEV 1 ) and arterial hypoxemia (PaO 2 ) educe the risk of early relapse, treatment failure, and length of hospital stay A dose of 40 mg prednisone per day for 5 days is recommended Prescribing Strategy for COPD 1. Short acting anticholinergic PN or SA Beta 2 PN, then 2. Long acting anticholinergic or LABA; plus rescue med, then 3. ICS + LABA or LA anticholinergic; plus rescue med, then 4. ICS + LABA and/or LA anticholinergic; plus rescue med *Theophylline is an alternate treatment but not preferred (relatively inexpensive) **PDE4: phosphodiesterase inhibitor (roflumilast, Daliresp) used to reduce exacerbations for patients with chronic bronchitis, severe airflow limitation and frequent exacerbations not controlled by LABAs
13 COPD oflumilast (Daliresp) New class: oral tablet phosphodiesterase 4 inhibitors MOA: increases camp in lung cells educes lung inflammation eserve for severe or very severe COPD; to reduce recurrent exacerbations COPD oflumilast (Daliresp) Maximize other inhalers first $255.99/month Watch out for 3A4 drug interactions COPD oflumilast (Daliresp) Watch for insomnia, weight loss, depression, change in mood Global Strategy for Diagnosis, Management and Prevention of COPD Differential Diagnosis: COPD and Asthma COPD Onset in mid-life Symptoms slowly progressive Long smoking history ASTHMA Onset early in life (often childhood) Symptoms vary from day to day Symptoms worse at night/early morning Allergy, rhinitis, and/or eczema also present Family history of asthma 2015 Global IniKaKve for Chronic ObstrucKve Lung Disease NAEPP The National Asthma Education and Prevention Program: Expert Panel eport 3, Guidelines for the Diagnosis and Management of Asthma -- Full eport 2007 Effective Asthma Management Preventive approach egularly scheduled visits (assess symptoms, pulmonary function is monitored, medications adjusted, ongoing education) 13
14 Medications Bronchodilators Corticosteroids Leukotriene blockers Bronchodilators Every asthma patient NEEDS a short acting BD This is a safety issue!!! Short acting ß agonists elief of acute symptoms only emember the ule of 2s These do NOT relieve inflammation Never as monotherapy for any persistent asthma What s the difference between the ß-2s? Drug ß-2 potency Onset in minutes Duration in hrs Albuterol 2 Within Pirbuterol 5 Within 5 5 Levalbuterol??? Within 5 8 Overuse of short acting ß-2? Decreased sensitivity to beta agonists if used on a chronic basis Doesn t work as well Overuse of short acting ß-2? Downregulation of beta-2 adrenergic receptors (there is a decrease in the number of ß-2 receptors) Uh oh! 14
15 What about the long acting ß-2? It can and does happen, but it is not observed as often as it is hypothesized It IS observed in SA agents Take Away Points Changes in the cor9costeroid molecule produce significant differences in potency (binding affinity at the glucocor9coid receptor) Binding affinity = Potency; Many factors impact improvement in lung func9on: Steroid, delivery device (MDI, DPI, NEB), addi9on of a spacer, facemask; pa9ent technique Kelly,HW. The Annals of Pharmacotherapy. 2009;43(3): Comparison of Steroids Dose (mg) ela9ve An9- inflammatory Ac9vity Dura9on of Ac9on Hours Cor9sol Prednisone Prednisolone Methylprednisolone Dexamethasone Good Steroid Choices Asthma: prednisone or prednisolone (less mineralocor9coid ac9vity) COPD: Methylprednisolone, prednisone (men9oned in GOLD guidelines) Last Points Adrenal insufficiency: hydrocor9sone used to help retain retain sodium and water Give prednisone, methylprednisolone, prednisolone once daily to minimize HPA axis suppression Proper9es of Inhaled Steroids Drug eceptor Binding Affinity Lung Delivery % Beclomethasone dipropionate/17- monopropionate 0.4/ Budesonide Ciclesonide/ desciclesonide 0.12/ Flunisolide Flu9casone propionate Mometasone furoate Triamcinolone acetonide
16 Leukotriene Blockers (LTA) Montelukast (Singulair) Zafirlukast (Accolate) Take Home Point! LTA: consider for mild asthma IF a patient can t or won t use an inhaled steroid Steroids are preferred for ANY form of persistent asthma Prevent remodeling!!!! Moderate or Severe Persistent Pharmacologic Asthma Management 4. Steroid plus bronchodilators Combined mechanism as for steroid and bronchodilators Examples: fluticasone plus salmeterol (Advair), budesonide plus formoterol (Symbicort), mometasone plus salmeterol (Dulera) No generics, very expensive!!! Take Home Points! Allergic hinitis: STEOIDS, second gen antihistamines COPD: Bronchodilators Asthma: STEOIDS Take Home Points! Make Evidence Based treatment decisions! Thank you! For ques9ons or to contact me: Dr. Amelie Hollier amelie@apea.com Advanced Practice Education Associates Lafayette, LA 16
Objectives. Speaker has no relationship to disclose. Sneezes, Wheezes, and Respiratory Diseases: An update on Asthma, Allergic Rhinitis,
Sneezes, Wheezes, and Respiratory Diseases: An update on Asthma, Allergic Rhinitis, and COPD Amelie Hollier, DNP, FNP-BC, FAANP Advanced Practice Education Associates Objectives Evaluation of medications,
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationAllergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma
Allergies and Asthma Presented By: Dr. Fadwa Gillanders, Pharm.D Clinical Pharmacy Specialist May 2013 Objectives Understand the relationship between asthma and allergic rhinitis Understand what is going
More information31 - Respiratory System
31 - Respiratory System Asthma 1. Asthma has two components. Name the two components. 2. What are the common triggers of asthma? (LP p319) (e.g., pets) Upper respiratory infections ( ) 3. Describe a normal
More informationMedications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationAsthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationTriage Information: 1. Duration of HPSJ Membership 2. Age 3. Fill history of Seasonal Allergy Medications
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Seasonal Allergy Medications LAST REVIEW: 5/28/2015 THERAPEUTIC CLASS: Rheumatologic/Immunologic REVIEW HISTORY: 5/15, 9/14
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationREVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE
REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: This form should be completed during the participant s clinic visit. 1) Are you regularly
More informationThe Medical Letter. on Drugs and Therapeutics. Drug Some Formulations OTC/Rx Usual Dosage Comments Class Comments Cost 1
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationARIA. At-A-Glance Pocket Reference 2007
ARIA_Glance_2007_8pg:ARIA_Glance_English 9/14/07 3:10 PM Page 1 ARIA At-A-Glance Pocket Reference 2007 1 st Edition NEW ARIA UPDATE BASED ON THE ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA WORKSHOP REPORT
More informationAllergic Rhinitis: When to Refer to an Allergist
Allergic Rhinitis: When to Refer to an Allergist Kirsten Kloepfer, MD, MS Assistant Professor of Pediatrics Section of Pulmonary, Allergy and Sleep Medicine Disclosures NIH K23 American Academy of Allergy,
More informationAllergy and inflammation
and inflammation 1 Allergic population hyper-producers of IgE consistently increasing western societies: ~20% of general population 2 Allergic population 3 Allergic triggers 4 Allergic triggers abnormal
More informationFoundations of Pharmacology
Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids
More informationFerris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationAsthma COPD Update 2018
Asthma COPD Update 2018 Roger Hefflinger, Pharm.D. Clinical Associate Professor ISU COP Clinical Teaching Pharmacist Family Medicine Residency of Idaho In support of improving patient care, Idaho State
More informationAsthma. Definition. Symptoms
Asthma Definition Asthma is a condition in which your airways narrow and swell and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath. For some
More informationMANAGING ASTHMA. Nancy Davis, RRT, AE-C
MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 03/03/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Xolair (omalizumab) Commercial HMO/PPO/CDHP HMO/PPO/CDHP: Rx
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationNancy Davis, RRT, AE-C
Nancy Davis, RRT, AE-C Asthma Statistics 25.6 million Americans diagnosed with asthma 6.8 million are children 10.5 million missed school days per year 14.2 lost work days for adults Approximately 10%
More informationEnd Stage COPD Guidance Document
End Stage COPD Guidance Document Suggested Guidelines for the Determination of Hospice Eligibility A patient with severe chronic pulmonary disease that meets the following criteria may be eligible for
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationAllergic Rhinitis 6/10/2016. Clinical and Economic Impact. Clinical and Economic Impact. Symptoms. Genetic/Environmental factors
I have no disclosures to make other than I too suffer from allergic rhinitis Allergic Rhinitis Betsy Close, MD Assistant Professor UT College of Medicine, Department of Family Medicine Clinical and Economic
More informationOral Agents. Formulary Limits. Available Strengths. IR: 4mg ER: 12mg Syrup: 2mg/5ml
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Seasonal Allergy Medications LAST REVIEW: 9/20/2016 THERAPEUTIC CLASS: Rheumatologic/Immunologic REVIEW HISTORY: 5/16, 5/15,
More informationInhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationLatest advances in the management of childhood allergic rhinitis
Latest advances in the management of childhood allergic rhinitis Jason Y K Chan Assistant Professor Department of Otorhinolaryngology, Head & Neck Surgery The Chinese University of Hong Kong Disclosures
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationOral Agents. Fml Limits. Available Strengths NF NF
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Allergy Medications LAST REVIEW: 9/12/2017 THERAPEUTIC CLASS: Rheumatologic/Immunologic REVIEW HISTORY: 9/16, 5/15, 9/14
More informationAIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol
DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationSelect Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationDrugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN
Drugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN Goals of Therapy Asthma Prevent symptoms COPD Reduce COPD symptoms Decrease use of SABAs Maintain normal pulm function & prevent loss
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationFASENRA (benralizumab)
FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationJagdeep Hundal, MD, Otolaryngology, Head & Neck Surgery 774 Christiana Rd, Suite B4, Newark, DE Phone: Fax:
Allergy Questionnaire Patient Name Date / / 1. What symptoms do you suffer from? Please circle below Eyes: Itchy eyes, tearing, eye redness, eye discharge Ears: Popping sensation, fullness, itching Nose/Sinus:
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationreslizumab (Cinqair )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease CareOregon Pharmacy Abridged sample of presentation content Home Equipment Pathophysiology Exacerbations Guidelines Lifestyle Modification Medication Management Sample
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationMedications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
More informationImproving Outcomes in COPD
Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea
More informationAssessing Severity. Management of Stable COPD. General Approach. Short Acting Bronchodilators. Staging System (GOLD)
William P. Saliski Jr. DO Montgomery Pulmonary Consultants Management of Stable COPD Pharmacotherapy Oxygen Smoking Cessation Vaccinations Rehabilitation Surgery Future Discussions Assessing Severity Staging
More informationCase Study. Allergic Rhinitis 5/18/2015
John A. Fling, M.D. Professor Allergy/Immunology University of North Texas Health Science Center, Fort Worth, Texas Case Study 38 year old male with a history of nasal congestion, clear nasal discharge
More informationIncorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.
Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate
More informationDrug Effectiveness Review Project Summary Report
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPREPARATION FOR ALLERGY TESTING *** Please read this information at least one week before your upcoming visit.
PREPARATION FOR ALLERGY TESTING *** Please read this information at least one week before your upcoming visit. In order to obtain valid and useful skin testing results, you will need to stop the use of
More information(pedi) Patient Name: date of birth:
(pedi) Patient Name: date of birth:_ Date: I am being seen on: a) self referral _ b) physician referral from Dr. Please share the main reasons for your office visit today (check all those that apply):
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationNew Therapies for Asthma
New Therapies for Asthma Tracy Bridges, MD Speaker Disclosure: Dr. Bridges participates in speaker bureaus for Teva, Genetech & Astra Zeneca. Objectives: Discuss the use of LAMA s for Asthma Detail the
More informationANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component
ANTINEOPLASTIC DRUGS CHAPTER 21 Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component Tx of malignancies Antineoplastic drugs: methotrexate
More informationASTHMA IN THE PEDIATRIC POPULATION
ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center
More informationAsthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways.
Asthma Asthma Description Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways. Symptoms of asthma In susceptible individuals, this inflammation causes recurrent
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationKey features and changes to these four components of asthma care include:
Guidelines for the Diagnosis and Management of Asthma in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding
More informationPharmacotherapy for Allergic Rhinitis
Pharmacotherapy for Allergic Rhinitis William Reisacher, MD FACS FAAOA Assistant Professor Weill Cornell Medical College The Impact of Allergic Rhinitis Allergic rhinitis affects approximately 50 million
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationCOPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator
Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules
More informationReport generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Section.
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ACLIDINIUM BROMIDE bronchodilators ADRENALINE/EPINEPHRINE
More informationAdvanced Pharmacology Respiratory Pharmacology
Advanced Pharmacology Respiratory Pharmacology Thomas W. Barkley, Jr., PhD, ACNP BC, FAANP President, Barkley & Associates www.npcourses.com and Professor of Nursing Director of Nurse Practitioner Programs
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationSinusitis. What are the sinuses? Who develops sinusitis?
Sinusitis Health experts estimate that 37 million Americans are affected by sinusitis every year. Americans spend nearly $6 billion each year on health care costs related to sinusitis. Sinusitis is an
More informationUsing Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?
Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Lindsay Thomas, Pharm.D. PGY2 Ambulatory Care Resident Department of Pharmacotherapy and Pharmacy
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationImpact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients
Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Maren A. McGurran, PharmD, BCPS; Lisa M. Richter, PharmD, BCPS, BCCCP; Nathan D. Leedahl,
More informationSecretary for Health and Family Services Selections for Preferred Products
Secretary for Health and Family Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Secretary for Health and Family Services based
More informationMethacholine Challenge Test
PATIENT & CAREGIVER EDUCATION Methacholine Challenge Test This information will help you prepare for your methacholine challeng e test at Memorial Sloan Kettering (MSK). A methacholine (meth-a-kole-leen)
More informationCOPD. Understanding. An educational health series from National Jewish Health IN THIS ISSUE. What is COPD? 2. How is COPD Managed?
Understanding COPD The Mount Sinai National Jewish Health Respiratory Institute was formed by the nation s leading respiratory hospital National Jewish Health, based in Denver, and top ranked academic
More informationQuestion I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device
What Device am I Class Side Effects History Potpourri Monitoring Tools 10 10 10 10 10 20 20 20 20 20 30 30 30 30 30 40 40 40 40 40 50 50 50 50 50 WHAT KIND OF DEVICE AM I? I was one of the first dry power
More informationDiagnosis and Management of Asthma
Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:
More informationWhat is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
More informationDrugs Used to Treat Chronic Obstructive Pulmonary Disease (COPD)
Drugs Used to Treat Chronic Obstructive Pulmonary Disease (COPD) COPD COPD is a chronic, irreversible obstruction of airflow that is usually progressive. Symptoms include cough, excess mucus production,
More informationCOPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial
More informationRespiratory Pharmacology
Allergy Targets of allergies Type I Histamine Leukotrienes Prostaglandins Bradykinin Hypersensitivity reactions Asthma Characterised by Triggered by Intrinsic Extrinsic (allergic) Mediators Result Early
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Grastek, Oralair, Ragwitek) Reference Number: CP.CPA.111 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of
More informationAsthma By Mayo Clinic staff
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationMatt Stumpe, MD Otolaryngologist Mid Kansas Ear, Nose, & Throat
Matt Stumpe, MD Otolaryngologist Mid Kansas Ear, Nose, & Throat Inflammation of the nasal mucosa secondary to an inappropriate hypersensitivity reaction to an allergen IgE mediated immune response with
More informationQUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
More informationVolume 4; Number 4 April 2010 PRESCRIBING GUIDANCE FOR HAY FEVER: SPRING / SUMMER 2010
Volume 4; Number 4 April 2010 PRESCRIBING GUIDANCE FOR HAY FEVER: SPRING / SUMMER 2010 PACEF Recommendations Recommended medicines remain the same as in recent years: Non-sedating antihistamines: generic
More informationLungs SLO Practice (online) Page 1 of 5
Lungs SLO Practice (online) Page 1 of 5 1. A 15 year- old teen has asthma. A nebulizer treatment has been ordered. The type of medication most likely to be used in this treatment for asthma management
More informationAsthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives
Asthma & COPD Medication Review Anna Meador, PharmD, BCACP Assistant Professor/ Pharmacy Director McWhorter School of Pharmacy/ Christ Health Center Amber Hutchison, PharmD, BCPS Assistant Clinical Professor
More informationAsthma Pharmacotherapy 2017: Stepwise Approach to Managing Asthma
Asthma Pharmacotherapy 2017: Stepwise Approach to Managing Asthma Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, APRN, NP-C, AE-C Director, Commercial Care
More informationAsthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Medication Acronyms SABA: Short acting
More informationDose. Route. Units. Given. Dose. Route. Units. Given
Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening
More informationRespiratory Medications and Devices Update 2/15
Respiratory Medications and Devices Update 2/15 Dewey Hahlbohm, PA-C, AE-C Wendy Brown, Pharm.D., MPAS, PA-C, AE-C Objectives! Review mechanism of action for asthma pharmacologic agents! Describe key patient
More informationUPDATE ON ASTHMA MEDICATIONS INCLUDING BIOLOGICS FOR SEVERE PERSISTENT ASTHMA JOAN O LEAR FNP AE- C KENWOOD ALLERGY AND ASTHMA CENTER
JOAN O LEAR FNP AE- C KENWOOD ALLERGY AND ASTHMA CENTER UPDATE ON ASTHMA MEDICATIONS INCLUDING BIOLOGICS FOR SEVERE PERSISTENT ASTHMA OBJECTIVES Describe Describe asthma medications that have been added
More information